Glyx Therapeutics Joins the Brain&Mind Community
October 2026 — Amiens, France Glyx Therapeutics has joined the Brain&Mind community, a strategic step in the development of our molecules targeting tauopathies. What this brings to Glyx Access to a network of experts specialized in neuroscience and neurodegenerative diseases Synergies with other players engaged in research on cognitive disorders Collaboration opportunities to accelerate the […]
